Selling drugs at a high price has never been a good idea, more so, if one increases the price in an election year. And recent developments in the US should send a clear message to Indian pharma majors.
Sun Pharma subsidiary, Taro Pharmaceuticals, in its filings to the US Securities and Exchange Commission, said that on September 8, 2016, Taro USA, and two of its senior officers, have received a grand jury subpoena from the Antitrust Division of US Department of Justice, which sought documents related to corporate and employee records, generic pharmaceutical products and pricing, communications with competitors and others regarding the sale of generic pharmaceutical products. “Taro intends to respond to the subpoena and, otherwise, cooperate with the Department of Justice investigation,” the company informed. It is, however,…